Neurology® Podcast

Latest Episodes:

Responsible Opioid Prescribing—Special Podcast #2 May 03, 2017

Show notes

We are producing and releasing 4 special podcast interviews this month dedicated to responsible opioid prescribing. We are doing this largely as a response to the ongoing opioid epidemic in the U.S. and around the world. In Special Podcasts 1 and 2, Dr. Ted Burns interviews Dr. Charles Argoff from Albany Medical College in New York. Many state boards in the U.S. are now requiring a few hours of CME for responsible opioid prescribing practices, and these podcasts may be eligible for a total 2 hours of Category 1 CME, however please check with your individual U.S. state Board of Medicine mandates. Regardless of CME, we felt these topics deserved covering and we hope you check out all four episodes and find them helpful and informative.

Responsible Opioid Prescribing—Special Podcast #1 May 03, 2017

Show notes

May 2 2017 Issue May 02, 2017

Show notes

Show description/summary:1) Outcome of intracerebral hemorrhage associated with different oral anticoagulants2) Neurology Resident & Fellow section yearly recruitmentThis podcast begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the May 2, 2017 issue of Neurology®. In the first segment, Dr. Andrew Southerland talks with Dr. David Werring about his paper on outcome of intracerebral hemorrhage with oral anticoagulants. Then, for our "What's Trending" feature of the week, Dr. Southerland focuses his interview with Dr. John Millichap on recent updates regarding the Neurology Resident & Fellow section. Disclosures can be found at Neurology.org. DISCLOSURES: Dr. Werring has served on scientific advisory boards for Allergan, Bayer, IXICO, and Amgen; has received speaker honoraria from Bayer; has served on the editorial board of the European Stroke Journal; has received publishing royalties from Cambridge University Press; has been a consultant for Ixico Ltd.; and has received research support from Pfizer, the Department of Health/Higher Education Funding Council For England, the Stroke Association/British Heart Foundation, and the Rosetrees Trust.Dr. Southerland serves as Podcast Deputy Editor for Neurology; receives research support from the American Heart Association-American Stroke Association National Clinical Research Program, American Academy of Neurology, American Board of Psychiatry and Neurology, Health Resources Services Administration and the NIH; has a provisional patent application titled: "Method, system and computer readable medium for improving treatment times for rapid evaluation of acute stroke via mobile telemedicine;" and gave legal expert review. Dr. Millichap has received speaker honoraria from Invitae; serves on the editorial board for Neurology and Pediatric Neurology Briefs; receives publishing royalties from BMJ Best Practice and UpToDate; and has received research support from UCB Pharma, Thrasher Research Fund, and Citizens United for Research in Epilepsy.

April 18 2017 Issue Apr 24, 2017

Show notes

Show description/summary:1) Epidemiology and Prognosis of Mild Traumatic Brain Injury in Returning Soldiers: A Cohort Study2) What's Trending: Alemtuzumab treatment and multiple sclerosisThis podcast begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the April 18, 2017 issue of Neurology. In the first segment, Dr. Michael Jaffee talks with Dr. Karen Schwab about her paper on mild traumatic brain injury in returning soldiers. For our "What's Trending" feature of the week, Dr. Mark Keegan talks with Dr. Gavin Giovannoni about his paper on alemtuzumab treatment and multiple sclerosis. For more information on traumatic brain injury services for active duty military and veterans, please visit the Defense and Veterans Brain Injury Center website at http://dvbic.dcoe.mil. Disclosures can be found at Neurology.org.DISCLOSURES: Dr. Jaffee serves on the scientific advisory board for Neurohabitation, Inc., and has received research support from the Florida State Department of Elderly Affairs.Dr. Schwab receives research support from Congressionally Directed Medical Research Programs (Grant #W81XWH-08-2-0105).Dr. Keegan serves on the editorial board for Multiple Sclerosis and Related Disorders; served as eMedicine Chief Editor from 2009 to 2015; receives publishing royalties for Common Pitfalls in Multiple Sclerosis and CNS Demyelinating Diseases: Case-Based Learning (Cambridge University Press 2016); consults for Novartis, Bristol Meyers Squibb, and Bionest; and received research support from Biogen for the ARISE study.Dr. Giovannoni consulted and served on scientific advisory boards for Biogen-Idec, Fiveprime, Genzyme, GW Pharma, Ironwood, Merck-Serono, Novartis, Roche, Sanofi-Aventis, Synthon BV, Teva, Vertex Pharmaceuticals, Abbvie, and Canbex; receives speaker honoraria from Biogen-Idec, Genzyme, GW Pharma, Merck-Serono, Novartis, Roche, and Teva Pharmaceuticals; serves as an editor for Multiple Sclerosis and Related Disorders; served on speaker's bureaus for Novartis and Teva; and received research support from Genzyme and Merck.

April 25 2017 Issue Apr 24, 2017

Show notes

Show description/summary:1) Practice guideline summary: Sudden unexpected death in epilepsy 2) What's Trending: 21st Century Cures ActThis podcast begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the April 25, 2017 issue of Neurology. In the first segment, Dr. Andrew Schomer interviews Dr. Cynthia Harden about the AAN practice summary guideline on sudden unexpected death in epilepsy (SUDEP). Then, for our "What's Trending" feature of the week, Dr. Jason Crowell talks with Dr. Nicholas Johnson about the 21st Century Cures Act. Disclosures can be found at Neurology.org.DISCLOSURES: Dr. Johnson serves as Associate Editor for Neurology: Genetics; receives research support from Ionis Pharmaceuticals, Biogen Idec, Balerion Therapeutics, Cytokinetics, Acceleron, NINDS (grant 1K23NS091511-01), Muscular Dystrophy Association, and Myotonic Dystrophy Foundation; and consults for AMO Pharma and AveXis. Dr. Schomer, Harden, and Crowell report no disclosures.

April 11 2017 Issue Apr 10, 2017

Show notes

Show description/summary:1) Intracerebral hemorrhage location and outcome among clinical trial participants 2) What's Trending: childhood amnesiaThis podcast begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the April 11, 2017 issue of Neurology. In the first segment, Dr. Andrew Schomer talks with Dr. Craig Anderson about his paper on intracerebral hemorrhage location and outcome among clinical trial participants. Then, for our "What's Trending" feature of the week, Dr. Ted Burns talks with Dr. Cristina Alberini about her paper on childhood amnesia. Disclosures can be found at Neurology.org.DISCLOSURES: Dr. Anderson served on scientific advisory boards for Astra Zeneca and Medtronic; receives honoraria and travel funding from Takeda China and Boehringer Ingelheim; serves on editorial boards for Stroke, Cerebrovascular Diseases, and International Journal of Stroke; and receives research support from the National Medical Research Council of Australia (grants 1052555, 1020462, and 1081356).Dr. Alberini serves on editorial boards for Neural Plasticity, Journal of Cell Science, Frontiers in Neuroscience, Neurobiology of Learning and Memory, Behavioral Neuroscience, Learning and Memory, European Brain Research Institute (EBRI) International Scientific Council (ISC), and Cellular and Molecular Neuroscience of Hippocampus. Dr. Burns serves as Podcast Editor for Neurology®; and has received research support for consulting activities with UCB, CSL Behring, Walgreens and Alexion Pharmaceuticals, Inc. All other participants report no disclosures.

Delayed Recall - Motor neuron disorders (April 2017) Apr 04, 2017

Show notes

The first interview is with Dr. Ted Burns and Dr. Merit Cudkowicz on the topic of ALS. This interview was part of the January 31, 2017 episode. The second interview, from October 25, 2016, is with Dr. Nath on HERV-K and ALS. In the third and final interview, originally released on February 28, 2017, Dr. Burns speaks with Dr. Richard Finkel about nusinersen and spinal muscular atrophy.

April 4 2017 Issue Apr 03, 2017

Show notes

Show description/summary:1) Reduction in Time to Treatment in Pre-hospital Telemedicine Evaluation and Thrombolysis2) What's Trending: gut microbiota regulate motor deficits and neuroinflammation in Parkinson diseaseOur podcast has changed to a two-segment format! Enjoy two in-depth interviews each week, starting with one featured article from the Neurology® family of journals followed by an interview on a trending topic or on a notable article from Neurology Today.This podcast begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the April 4, 2017 issue of Neurology. In the first segment, Dr. Andy Southerland interviews Dr. Shazam Hussain about his paper on time-to-treatment in pre-hospital telemedicine evaluation and thrombolysis. Then, for our "What's Trending" feature of the week, Dr. Alberto Espay talks with Dr. Sarkis Mazmanian about his paper on how gut microbiota regulate motor deficits and neuroinflammation in Parkinson Disease. Disclosures can be found at Neurology.org.DISCLOSURES: Dr. Southerland serves as Podcast Deputy Editor for Neurology; receives research support from the American Heart Association-American Stroke Association National Clinical Research Program, American Academy of Neurology, American Board of Psychiatry and Neurology, Health Resources Services Administration and the NIH; has a provisional patent application titled: "Method, system and computer readable medium for improving treatment times for rapid evaluation of acute stroke via mobile telemedicine;" and gave legal expert review.Dr. Hussain served on scientific advisory boards for pulsar neurovascular, penumbra, Inc., and Prolong Medical.Dr. Espay serves as Associate Editor for the Journal of Clinical Movement Disorders; serves as an editorial board member of Parkinsonism and Related Disorders and The European Neurological Journal; serves on the scientific advisory board for Solvay Pharmaceuticals, Inc. (now Abbvie), Chelsea Therapeutics International, Ltd., Teva Pharmaceutical Industries Ltd., Impax, Merz Pharmaceuticals, Inc., Pfizer Inc, Solstice Neurosciences, Eli Lilly and Company, ACADIA Pharmaceuticals, Inc. and USWorldMeds; is a consultant for Chelsea Therapeutics International, Ltd., Solvay Pharmaceuticals, Inc. (now Abbvie), ACADIA Pharmaceuticals, Inc., Cynapsus and Lundbeck, Inc; receives royalties for publications of books from Lippincott, Williams & Wilkins and Cambridge University Press; serves on the speakers' bureau of UCB, Teva Pharmaceutical Industries Ltd., American Academy of Neurology and Movement Disorders Society; receives research support from the CleveMed/Great Lake Neurotechnilogies, Michael J. Fox Foundation and the NIH.For full disclosures, please contact Dr. Mazmanian directly at sarkis [at] caltech.edu.

March 28 2017 Issue Mar 27, 2017

Show notes

1) Early Decompressive Craniectomy for Malignant Cerebral Infarction: Meta-analysis and Clinical Decision Algorithm2) What's Trending: Update on the Resident and Fellows section 3) Topic of the Month: Brain tumors - gliomasThis podcast begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the March 28, 2017 issue of Neurology. In the first segment, Dr. Bryan Eckerle talks with Dr. Bradley Molyneaux and Dr. Christopher Streib about their Neurology® Clinical Practice paper on early decompressive craniectomy for malignant cerebral infarction. Dr. Ted Burns talks with Dr. Roy Strowd about recent updates regarding the Neurology® Resident & Fellows section for our "What's Trending" feature of the week. In the next part of the podcast, Dr. Kait Nevel focuses her interview with Dr. David Schiff on gliomas. Disclosures can be found at Neurology.org. DISCLOSURES:Dr. Molyneaux has received research support from Remedy Pharmaceuticals, Inc.Dr. Streib has served on the Institute for Clinical Systems Improvement (ICSI) Stroke Guidelines Committee (no reimbursement).Dr. Burns serves as Podcast Editor for Neurology®; and has received research support for consulting activities with UCB, CSL Behring, Walgreens and Alexion Pharmaceuticals, Inc. Dr. Strowd serves on the editorial board of Neurology (Resident & Fellow section); and has received research support from the Wake Forest School of Medicine Center for Translational Sciences Award, the KL2 Career Development Award, and the American Academy of Neurology.Dr. Schiff has served on the scientific advisory boards of Genetech, Celldex, Orbus, and Vascular Biogenics Oxigene; has received travel funding/speaker honoraria from Merck; serves on the editorial boards of Neurology, Neurosurgery, Neuro-Oncology, and Lancet Neurology; receives publishing royalties from UpToDate, and has been a consultant for Cavion.All other participants report no disclosures.

March 21 2017 Issue Mar 20, 2017

Show notes

1) Pure autonomic failure: Predictors of conversion to clinical CNS involvement2) What's Trending: ocrelizumab in multiple sclerosis 3) Topic of the Month: neuro-oncologyThis podcast begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the March 21, 2017 issue of Neurology. In the first segment, Dr. Jeff Ratliff interviews Dr. Wolfgang Singer about his paper on pure autonomic failure. For our "What's Trending" feature of the week, Dr. Mark Keegan talks with Dr. Stephen Hauser about his paper on ocrelizumab in multiple sclerosis. In the next part of the podcast Dr. Kait Nevel focuses her interview with Dr. Lisa DeAngelis on metastatic disease. Disclosures can be found at Neurology.org.DISCLOSURES:Dr. Singer serves as Associate Editor for Clinical Autonomic Research; serves on the Autonomic Neuroscience: Basic and Clinical editorial board; holds a patent for use of 3,4 diaminopyridine in the treatment of orthostatic hypotension and postural tachycardia syndrome; received research support from NH, FDA, Cure MSA Foundation, Dysautonomia International, and American Dysautonomia Institute. Dr. Keegan serves on editorial boards for eMedicine (Chief Editor 2009-2015) and Multiple Sclerosis and Related Disorders; receives publishing royalties from Common Pitfalls in Multiple Sclerosis and CNS Demyelinating Diseases: Case-Based Learning Cambridge University Press 2016; consulted for Novartis, Bristol Meyers Squibb, and Bionest Partners; and received research support from Terumo Corporation and BCT International Ltd.Dr. Hauser serves on scientific advisory boards for Bionure, Annexon, Symbiotix, Neurona, and Molecular Telescope; receives publishing royalties from Harrison's Principles of Intervnal Medicine (McGraw Hill 1994); holds stock options in Bionure, Annexon, Symbtiotix, all of which were transferred to University of California – San Francisco; and received funding from NIH, National Multiple Sclerosis Society, and the Conrad Hilton Foundation.Dr. DeAngelis serves on scientific advisory board for Celgene and CarThera; serves on editorial boards for Neurology, Neuro-Oncology, Journal of Neuro-oncology, and Neuro-Oncology Practice; receives publishing royalties from The Neurologic Complications of Cancer (Oxford University Press 2008); and receives research support from NIH.All other participants report no disclosures.

Our TOPPODCAST Picks

Follow Us

Stay Connected

Related Podcasts

Links

Stay Connected